We used serial protein misfolding cyclic amplification (sPMCA) to amplify the D10 strain of CWD prions in a linear relationship over two logs of D10 dilutions. The resultant PMCA-amplified D10 induced terminal TSE disease in CWD-susceptible Tg(cerPrP)1536 mice with a survival time approximately 80 days shorter than the original D10 inoculum, similar to that produced by in vivo sub-passage of D10 in Tg(cerPrP)1536 mice. Both in vitro-amplified and mouse-passaged D10 produced brain lesion profiles, glycoform ratios and conformational stabilities significantly different than those produced by the original D10 inoculum in Tg(cerPrP)1536 mice. These findings demonstrate that sPMCA can amplify and adapt prion strains in vitro as effectively and much more quickly than in vivo strain adaptation by mouse passage. Thus sPMCA may represent a powerful tool to assess prion strain adaptation and species barriers in vitro.
Introduction
According to the prion hypothesis, a proteinacious pathogen devoid of instructional nucleic acid initiates and propagates transmissible spongiform encephalopathies (TSEs), a group of invariably fatal, infectious neurological diseases (Prusiner, 1982) characterized by auto-conversion of the normal host cellular prion protein (PrP C ) into a misfolded, insoluble, proteinase K (PK)-resistant form (PrP RES ).
Mounting biochemical and biological evidence supports the prion hypothesis (Büeler et al., 1993; Hope et al., 1986; Oesch et al., 1985; Prusiner, 1982) . Prion infectivity correlates with PrP RES in brain homogenates from animals afflicted with TSEs, including sheep scrapie, bovine spongiform encephalopathy (BSE) and chronic wasting disease (CWD, (Bolton et al., 1982; Browning et al., 2004; Collinge et al., 1995a; Hope et al., 1988; Race et al., 2002; Scott et al., 1999) . More recently, synthetic prions made from truncated recombinant PrP have been shown to be infectious when inoculated into transgenic mice expressing the same isoform and in wild type mice upon subsequent passage (Legname et al., 2004) . Additional evidence has come from several reports that demonstrate in vitro generation of infectious hamster prions using serial protein misfolding cyclic amplification (sPMCA), a highly efficient amplification method employing repeated cycles of incubation of prions with normal brain homogenate (NBH) as a source of PrP C substrate to grow existing prion templates, and sonication to break the resulting large aggregates into smaller, more numerous prion templates (Castilla et al., 2005; Deleault et al., 2007; Murayama et al., 2007a; Weber et al., 2007) . sPMCA of PrP RES from mouse-adapted scrapie (PrP Sc ) and CWD prions (PrP CWD ) has recently been described (Kurt et al., 2007; Murayama et al., 2007b) , although infectivity of these amplified materials was not assessed.
The unique etiology of mammalian prion diseases complicates characterization, identification, and even the definition of prion strains. Traditionally, prion strains have been typed according to host range, incubation time to terminal disease and neuroanatomic lesion profiles based on seminal work comparing human and animal TSEs (Gajdusek et al., 1966; Gibbs and Gajdusek, 1971; Hadlow, 1959; Taraboulos et al., 1992) . Other criteria have been developed based on biochemical and biophysical properties of prions to investigate heritable structural differences among different prion strains, including size and extent of the PK-resistant core (Bessen and Marsh, et al.1994; Korth et al., 2003; Telling et al., 1996) , glycoform ratio and conformational stability upon chemical or thermal denaturation Hill et al., 1997; Peretz et al., 2001 Peretz et al., , 1997 Safar et al., 1993 Safar et al., , 1998 Scott et al., 2005) . These parameters have proven useful for identification of prion strains with similar origins, host ranges and pathology and to predict transmission barriers to heterologous host species (Collinge and Rossor, 1996; Raymond et al., 2000; Will et al., 1996) .
Experimental inoculation of animals represents the most reliable and accepted measure of efficiency of strain adaptation and transmission of prions into new hosts (Collinge et al., 1995a (Collinge et al., , 1995b Hamir et al., 2005 Hamir et al., , 2006a Hamir et al., , 2006b Hamir et al., , 2003 . However, these experiments often require extraordinarily long incubation periods, even by prion experimental standards, to fully assess strain adaptation and species barriers. Here we report efficient linear amplification of PrP CWD by sPMCA resulting in in vitro generation of infectious CWD prions. Remarkably, we observed a drastic, nearly identical reduction in incubation time to terminal disease of CWD-susceptible Tg(cerPrP) 1536 mice inoculated with in vitro-amplified or mouse-passaged prions from the D10 isolate of CWD prions when compared to the original D10 inoculum. In vitro-amplified and in vivo-passaged D10 also shared similar neuropathological and biochemical characteristics that were significantly different than the original D10 strain, more closely resembling the RML strain of mouse-adapted scrapie prions. By all accepted parameters used to characterize prion strains that we examined, sPMCA adapted the D10 CWD strain as efficiently as passage in Tg(cerPrP)1536 mice, and represents a powerful, efficient tool for assessing strain adaptation and species barriers in vitro.
Results

Linear amplification of PrP
CWD
In vitro amplification of PK-resistant PrP (PrP RES ) from CWD prions using protein misfolding cyclic amplification (PMCA) has recently been reported (Kurt et al., 2007 (Fig. 1E ).
Beginning with a 10 − 3 D10 dilution, we achieved a ten-fold amplification efficiency after one PMCA round, producing PrP CWD equivalent to a 10 − 2 dilution. Re-diluting this material 10 3 -fold produced a 10 − 5 dilution equivalent. We then amplified this material approximately 10 3 -fold, again producing a 10 − 2 equivalent dilution.
We continued this sPMCA strategy for six more rounds, oscillating between 10 − 5 and 10 − 2 equivalent dilutions upon re-dilution and PMCA to arrive at an overall D10 dilution of 10
, a point at which the original PrP RES inoculum has been estimated to be lost, and only amplified PrP RES is present in the sample (Castilla et al., 2005) .
Western blot analysis demonstrated the maintenance of a strong PrP RES signal in the amplified product throughout sPMCA, whereas unamplified samples were undetectable ( Fig. 2A) . Densitometric analysis revealed similar band intensities for PK-digested D10, amplified 10 − 24 D10 and mouse-passaged D10, with RML producing approximately half the intensity of the other three inocula (Fig. 2B) . We therefore inoculated Tg(cerPrP)1536 mice intracerebrally with 30 μl of each D10-derived inoculum diluted 1:10 in sterile 320 mM sucrose supplemented with antibiotics in PBS. All mice inoculated with amplified D10 contracted neurologic disease consistent with TSE with a mean incubation time to terminal illness of 169 ± 4 days post inoculation (DPI), while all mice inoculated with unamplified D10 are currently asymptomatic at N500 DPI (Table 1) . Surprisingly, Tg(cerPrP) 1536 mice inoculated with the original D10 strain contracted disease 82 days later (251 ± 3 DPI) than amplified D10-inoculated mice. Inoculation of Tg(cerPrP)1536 mice with mouse-passaged D10 (D10 Fig. 1 (Hill et al., 1999; Rubenstein et al., 1994) , normalizing prion inoculum by estimating PrP RES content may have resulted in imprecise measurement of prion doses that could explain the differences in mean incubation times that we observed in the mouse bioassay. We therefore analyzed these inocula by neuropathological and biochemical criteria previously used to assess other prion strain properties.
sPMCA and mouse passage of D10 changes CWD neuropathology
To compare CWD neuropathology of terminally sick mice inoculated with in vitro-amplified and mouse-passaged D10 to mice inoculated with the original D10 strain, we analyzed brain sections for vacuolation, astrogliosis, PrP RES deposition and amyloidogenicity ( . These deposits stained poorly with Thioflavin T (Fig. 3D) , indicating little or no amyloid structure. We observed increased neuropathology in the cerebellum, with more vacuolation (Figs. 3E-G), astrogliosis ( Fig. 3F ) and PrP RES deposition (Fig. 3G ). Thioflavin T stained a few deposits, revealing some amyloid structure (Fig. 3H ). In contrast, hippocampal sections of Tg(cerPrP)1536 mice inoculated with original D10 inoculum (D10 p1 mice) displayed extremely severe vacuolation (Figs. 3I-K), neuronal cell loss ( Fig. 3I ) and astrogliosis ( Fig. 3J ). Numerous PrP CWD deposits appeared more focal and dense ( Fig. 3K) and Thioflavin T stained these punctate plaques sharply, revealing a more defined, radially organized amyloid structure (Fig. 3L ). However, little or no cerebellar neuropathology was evident in these mice compared to Amp D10 p1 mice (Figs. 3M-P). Upon secondary passage of D10 (D10 p2 mice), we observed decreased neuropathology in the hippocampus similar to that found in Amp D10 p1 mice, with little or no vacuolation or neuronal cell loss (Figs. 3Q-S). The mild to moderate astrogliosis observed ( Fig. 3R ) was dramatically decreased compared to D10 p1 mice. Little or no PrP RES deposition was evident ( Fig. 3S ) and no Thioflavin T positive staining was observed (Fig. 3T ). In the cerebellum, we observed an increase in vacuolation, neuronal cell loss (Figs. 3U-W) and astrogliosis ( Fig. 3V ). We also observed faintly stained, diffuse PrP CWD deposits (Fig. 3W) , some of which were stained by Thioflavin T (Fig. 3X) . These rare amyloid structures appeared more diffuse and lacked the radially structured punctae clearly evident in amyloid from D10 p1 mice (Fig. 3L ). Hippocampal sections of wild type mice inoculated with RML exhibited vacuolation, neuronal cell loss ( Fig. 3Y) , astrogliosis ( Fig. 3Z ) and diffuse PrP Sc deposition ( Fig. 3AA ) typical of mouse scrapie and reminiscent of neuropathology observed in Amp D10 p1 and D10 p2 brains. We examined eight additional brain areas for neuropathology to generate lesion profiles for each inoculation group. We observed increased neuropathology, especially diffuse PrP RES deposition and vacuolation, in the dorsal medulla and cerebellum, with moderate to severe astrogliosis in the superior colliculus, red nucleus and thalamus in amplified and mouse-passaged D10-inoculated Tg(cerPrP)1536 mice and RML-inoculated wild type mice. We observed decreased overall neuropathology in these brain regions, and increased neuropathology in the hippocampus of Tg(cerPrP)1536 mice inoculated with the original D10 srain. Seven lesion profile scores for brains from Amp D10 p1, five for D10 p2 and six for RML infected mice differed from D10 p1 scores without overlapping standard deviations (SDs); while ≤3 lesion profile scores differed without overlapping SDs among brains from Amp D10 p1, D10 p2 and RML infected mice (Fig.  4) . Overall lesion severity also increased and neuroanatomic location was altered from D10 p1 to D10 p2 and Amp D10 p1 to more closely match severity and location of RML-induced lesions. Taken together, these data indicate that in vitro amplification and in vivo-passage of D10 changes CWD neuropathology to one that more closely resembles scrapie neuropathology in mice and further support the proposition that D10 strain adaptation has occurred in vitro and in vivo.
sPMCA and mouse passage of D10 changes PrP CWD glycoforms ratios
We next characterized these prion inocula biochemically by assessing PK-resistant fragment sizes and glycoform ratios, which have previously been used to characterize prion strains Hill et al., 1997) . While analysis of pooled brain homogenate from at least three mice from each group or three PMCA reactions revealed no differences in PK-resistant core fragment sizes, we did detect significant differences in glycoform ratios (Fig. 5A ). RML -fold dilution of D10 was subjected to serial PMCA (sPMCA). After each round, the sample was re-diluted 1:10 3 in fresh NBH and subjected to an additional 96 PMCA cycles. Fold-dilutions refer to the overall dilution relative to the starting dilution and were detected at the indicated round. Unamplified samples at each dilution (U) and unspiked normal brain (NB) were not detected. , which was further increased upon secondary passage (D10 p2). sPMCA of D10 also Thioflavin T failed to stain (D). Cerebellar neuropathology was more pronounced (E-H), with increased vacuolation (E), astrogliosis (F) and PrP CWD deposits (G), some of which were stained with Thioflavin T (H). In contrast, hippocampal sections from mice inoculated with the original D10 isolate exhibited more extensive neuronal cell loss and vacuolation (I-K) and astrogliosis (J), with dense, punctate plaques of PrP CWD (K) that stained sharply with thioflavin T (L), revealing more numerous amyloid structures that appeared punctate and radially organized. Little or no cerebellar neuropathology was observed in the brains of these mice (M-P). Upon second passage (D10 p2), little to no neuronal cell loss and vacuolation (Q-S) and mild to moderate astrogliosis (R) was evident in hippocampal sections, and PrP CWD deposition was much more diffuse (K) and lacked amyloidogenicity (T). However, cerebellar neuropathology was clearly evident, with increased neuronal cell loss, vacuolation (U-W), and PrP CWD deposits (W), some of which were amyloidogenic, but lacked the radially structured, punctate deposits found in D10 p1 plaques. Hippocampal sections from RML-infected wild-type mice exhibited vacuolation (Y) astrogliosis (Z) and diffuse PrP Sc deposition (AA) reminiscent of that produced by amplified D10 p1 and D10 p2 strains of CWD prions. Brain sections from D10-inoculaed PrP −/− mice were stained with H&E (AB), GFAP (AC), anti-PrP (AD) and Thioflavin T (AE) as negative controls. Scale bars, 50 μm.
shifted the glycoform ratio toward monoglycosylated PrP CWD . We did observe some variability in these trends when we analyzed brain homogenates from individual mice, especially among D10 p1 samples (Fig. 5B) . We therefore quantified band intensities from multiple western blots to more accurately assess glycoform ratios of all prion strains ( These data reveal similar glycoforms ratios of Amp D10 p1 and D10 p2 prion inocula that are significantly different from D10 and D10 p1 inocula.
sPMCA and mouse passage of D10 changes PrP CWD conformational stability
We further characterized these prion inocula biochemically by assessing conformational stability in the presence of GdnHCl, another established criteria for prion strain typing (Peretz et al., 2001 (Peretz et al., , 2002 Scott et al., 2005; Xie et al., 2006 (Fig. 6 ). Conformational stability was significantly reduced upon secondary passage of D10 (D10 p2, 2.03 ± 0.06 M, p b 0.01) and primary passage of amplified D10 (Amp D10 p1, 1.89 ± 0.06 M, p b 0.01) in Tg(cerPrP)1536. The RML prion strain was significantly less stable than all other strains (1.46 ± 0.01 M, p b 0.01). In toto, the biological, neuropathological and biochemical data reported here strongly support the conclusion that D10 strain adaptation has occurred in vitro and in vivo.
Discussion
The first demonstration of amplifying PrP CWD using PMCA was recently reported to yield an approximately 200-fold amplification efficiency per round (Kurt et al., 2007) . In this study we have increased this efficiency up to several thousand-fold per round by optimizing NBH preparation and sonication parameters. We also demonstrated the specificity of the reaction by using moPrP C substrates as negative controls. We observed a linear relationship between −fold amplification and D10 dilutions between 10 − 3 and 2 × 10
. Limiting substrate at lower dilutions and limiting prion templates at higher dilutions probably account for asymptotic amplification efficiencies. By maintaining PrP CWD concentrations in the dynamic range of PMCA, we were able to produce linear amplification over repeated PMCA rounds. This resulted in highly efficient and reproducible amplification over at least eight PMCA rounds that generated significant amounts of amplified 10 − 24 D10 with which we infected Tg(cerPrP) 1536 mice. Comparing equal dilutions of the original D10 inoculum and amplified 10 − 24 D10 by western blot confirmed that both samples displayed nearly identical signal intensities. We next demonstrated the first in vitro generation of infectious CWD prions using amplified 10 − 24 D10 as the inoculum. In vitroamplified D10 elicited terminal prion disease earlier than the original D10 used to seed the sPMCA reaction. This result was surprising because generation of infectious hamster-adapted scrapie prions in vitro using PMCA has previously been reported to elicit terminal disease later than the original scrapie inocula, a phenomenon largely abrogated by serial passage or by conjugation of amplified material to nitrocellulose prior to inoculation (Castilla et al., 2005; Deleault et al., 2007; Murayama et al., 2007a; Weber et al., 2007) . One possible explanation for this discrepancy is that previous studies used homologous brain inocula, substrates and hosts, whereas we used infected cervid brain as the prion inocula and Tg(cerPrP)1536 mice as a source for brain substrate and host. Primary passage of cervid-derived D10 into a murine host may decrease prion replication efficiency, which increases upon in vitro amplification using NBH from Tg(cerPrP)1536 mice as a substrate or secondary passage in Tg(cerPrP)1536 mice. Indeed, we observed a reduction in mean incubation time to terminal disease upon serial passage of D10 in Tg(cerPrP)1536 mice, in accordance with another recent report (Green et al., 2008) . These data implicate other host factors present in the brain that may influence prion amplification in vitro and in vivo, resulting in nearly identical CWD prion infectivity titres that we observed for sPMCAamplified and mouse-passaged D10. Many prion-forming cofactors have been proposed, including proteins (Kaneko et al., 1997; Telling et al., 1995; Yehiely et al., 1997) , polysaccharides (Appel et al., 1999; Dumpitak et al., 2005) or polyanions (Deleault et al., 2003 (Deleault et al., , 2005 ) that may facilitate host-specific prion amplification in vitro and in vivo.
Another possibility postulated by Soto and colleagues is that in vitrogenerated scrapie prions may have created a new prion strain that requires in vivo adaptation to acquire the same infectivity titre as the original prion strain (Castilla et al., 2005) . Our data supports this hypothesis, but because sPMCA generated a cervid prion strain using mouse NBH expressing cerPrP C , we conclude that strain adaptation occurred in vitro, resulting in a more infectious prion strain in mice. Correlation with our in vivo data demonstrating mouse adaptation of D10 following serial passage strongly supports this interpretation. Serial passage of natural sheep scrapie and bovine spongiform encephalopathy prion isolates in Tg(ovPrP) mice has also recently been shown to reduce incubation times (Baron and Biacabe, 2007; Bencsik et al., 2007) . As a corollary to the experiments conducted here, it would be interesting to determine whether sPMCA could be used to adapt natural scrapie isolates in vitro and increase their infectivity titres as does in vivo adaptation via mouse passage. Another straightforward explanation for the shortened incubation times we observed is that inocula from in vitro amplification and in vivo adaptation contains no heterologous brain homogenate present in the original D10 inoculum, abrogating a potential immune response that may clear a significant portion of the initial inocula. Seminal work comparing mouse and hamster prion titres in mice showed that hamster prions, containing heterologous hamster brain homogenate, induced disease much earlier than mouse prions containing homologous mouse brain homogenate, arguing against immune clearance significantly affecting prion titers (Büeler et al., 1993) . Indeed, we have never observed any clinical, cellular, biochemical or molecular evidence of inflammation upon i.c. inoculation with heterologous brain material (our unpublished data), most likely because the brain is a relatively immune privileged site. In the present study, if immune clearance simply lowered the effective D10 prion dose compared to in vitro-amplified or mouse-passaged D10 without strain adaptation, then both of these D10-derived strains should exhibit increased infectivity titres while maintaining other strain properties of the original D10. We explored this possibility by first comparing neuropathological properties of the original D10 strain, in vitroamplified and mouse-passaged D10, and RML. Both in vitro-amplified and in vivo-adapted D10 prions induced similar neuropathology in Tg (cerPrP)1536 mice, characterized by diffuse PrP CWD deposition that is similar to that observed in brains from wild type mice infected with RML, a scrapie strain well-adapted to the mouse (Chandler, 1961; Kingsbury et al., 1983; Prusiner et al., 1978) . These three prion strains produced PrP CWD deposition clearly different than the dense, punctate plaques evident in brains of Tg(cerPrP)1536 mice inoculated with the original D10 strain. Similar diffuse PrP RES deposition has been observed in RML-infected and CWD-infected mice expressing mouse PrP C (Sigurdson et al., 2006; Zabel et al., 2007) and scrapie-infected mice expressing bovine and mouse-bovine chimeric PrP C (Scott et al., 2005) . Amplified and mouse-passaged D10 and RML also produced similar brain lesion profiles that were consistent with neuropathology previously reported in scrapie-infected mice (Baringer and Prusiner, 1978; Eklund et al., 1967; Kingsbury et al., 1983) and distinct from the profile induced by the original D10 strain. The changes in location and severity of prion lesions evident among these prion strains are consistent with D10 strain adaptation by in vitro amplification that is indistinguishable from in vivo adaptation via passage of D10 in Tg (cerPrP)1536 mice. We also detected biochemical similarities among in vitro and in vivo-adapted prion strains. While sPMCA D10 and D10 p1 displayed nearly identical PrP CWD glycoforms ratios as the parental D10 strain, Amp D10 p1 and D10 p2 significantly increased monoglycosylated PrP CWD compared to the principally diglycosylated D10 strain, similar to the transition observed in another study of murine adaptation of CWD prions (Sigurdson et al., 2006) . These results are intriguing in light of another recent study demonstrating that host PrP C glycoforms dictate in vitro PrP Sc amplification efficiency (Nishina et al., 2006) , suggesting that perhaps murine PrP C glycoforms select, from a heterologous mixture, distinct strains of CWD prions that are preferentially amplified in vitro or in vivo. We also show that Amp D10 p1 and D10 p2 conformations were significantly more destabilized by GdnHCl denaturation compared to sPMCA D10 and D10 p1, the stabilities of which were nearly identical to that of D10. RML adopted a conformation that was by far the least stable of all prion strains investigated. Previous reports have documented relatively less stable mouse-passaged scrapie prion conformations and more stable CWD prion conformations (Green et al., 2008; Scott et al., 2005; Xie et al., 2006) . Our data demonstrate that serial passage of CWD prions in Tg(cerPrP)1536 mice can destabilize their conformation, and that sPMCA using Tg(cerPrP) NBH as substrate expedites this process. Interestingly, decreased stability of in vitro and in vivo-adapted D10 prion strains correlates with shortened incubation times in Tg(cerprP) 1536 mice, a phenomenon previously exhibited for other novel prion strains generated in vitro (Legname et al., 2005) and in vivo (Peretz et al., 2002) . We did not observe statistically significant changes in either glycosylation or conformational stability of sPMCA D10 or D10 p1, as one might expect if adaptation had occurred. Perhaps sPMCA and primary passage of D10 initiates creation of a new or intermediate prion strain, or selection of a small concentration of a pre-existing one that, upon further passage into mice, is preferentially selected and amplified. This interpretation is supported by the increased variability in the biochemical properties of D10 p1 (glycosylation and conformational stability) and sPMCA (conformational stability), which may indicate the emergence of nascent prion strains.
The similar neuropathological and biochemical characteristics of in vitro and in vivo-adapted D10 that clearly differentiate them from primary-passaged D10 prions strongly indicate that sPMCA has adapted D10 as effectively as in vivo adaptation by mouse passage. However, we cannot rule out the possibility that in vitro amplification and in vivo passage of D10 also increased the prion titre of these strains, either by strain adaptation, immune abrogation, or both. Unlike RML, whose titre has been determined by mouse bioassay and cell culture assays (Klohn et al., 2003; Prusiner et al., 1982) , exact titres for most scrapie and all CWD prion strains have yet to be determined. Comparing western blot signal intensities of PrP RES remains a crude estimate of prion infectivity because PrP RES concentration and prion infectivity do not always closely correlate (Hill et al., 1999; Rubenstein et al., 1994) . Here we present evidence for strain adaptation by sPMCA. The possibility of a concomitant increase in prion titre would also be a novel and interesting result of prion amplification by sPMCA. We conclude that in vitro D10 amplification parallels primary passage of D10 in Tg(cerPrP)1536 mice, and that sPMCA represents a viable means of adapting prion strains to new hosts. Since strain adaptation correlates with species barriers, we envision sPMCA to potentially be a powerful tool with which to probe strain differences and assess species barriers in a fraction of the time and cost of animal bioassays.
Materials and methods
Mice FVB mice were purchased from the Jackson Laboratories (Bar Harbor, ME). Tg(cerPrP)1536 and Tga20 mice were generated as previously described (Browning et al., 2004; Fischer et al., 1996) . All mice were bred and maintained at Lab Animal Resources, accredited by the Association for Assessment and Accreditation of Lab Animal Care International, in accordance with protocols approved by the Institutional Animal Care and Use Committee at Colorado State University.
Sources and preparation of prion inocula
The D10 isolate of CWD prions (D10) and the Rocky Mountain Lab strain of mouse-adapted scrapie prions passage 5 (RML) were previously described (Browning et al., 2004; Prusiner et al., 1978) . D10 was then passaged through Tg(cerPrP)1536 mice or amplified in vitro by serial protein misfolding cyclic amplification (sPMCA). 10% brain homogenates were prepared in PBS or PMCA buffer (4 mM EDTA, 150 mM NaCl in PBS). Densitometric analysis of PK-digested samples on western blots revealed similar band intensities of equal dilutions of D10, mouse-passaged D10, amplified 10 − 24 D10 and RML.
We therefore diluted equal volumes of each inoculum 1:10 in 320 mM sucrose supplemented with 100 U/mL Penicillin and 100 μg/mL Streptomycin (Gibco) in PBS 30 min prior to intracerebral inoculations.
Preparation of normal brain homogenate (NBH) and PMCA
Mice were euthanized and perfused with 30 ml 5 mM EDTA in PBS. Whole brains were removed and immediately frozen in liquid nitrogen. Brains were weighed and transferred into 1.5 mL Eppendorf tubes with 2.5 mm glass beads. PMCA buffer with 2× Complete Protease Inhibitor Cocktail (Roche) was added to make a 20% w/v solution. Samples were homogenized for 20 s at 4.5 m/s in a FastPrep machine (Biogene), cooled on ice for 2 min and centrifuged at 14,000 ×g for 10 s to reduce foaming. This process was repeated twice. NBH was diluted to a 10% w/v solution by adding an equal volume of PMCA conversion buffer containing 2% Triton X-100 and incubated on ice for 20 min. NBH was clarified by centrifuging for 30 s at 1500 ×g and supernatants were aliquoted to into new tubes and stored at −70°C. PMCA was modified from a previous protocol (Kurt et al., 2007) . Briefly, 50 μL samples of D10 diluted into 10% NBH were placed into wells of a 96-well microplate. The entire plate was suspended in the water bath of a 3000MP sonicator (Misonix) and sonicated at 70-85% maximum power for 40 s, followed by a 30-minute incubation at 37°C. This cycle was repeated 96 times. For sPMCA, 50 μL of a 10 − 3 D10 dilution in NBH was subjected to PMCA. 50 μL of a 10 − 3 dilution of amplified material in fresh NBH was subjected to another PMCA round. This process was repeated for a total of eight rounds.
PK digestion and western blotting
Samples were digested with 50 μg/ml PK (Roche) for 30 min at 37°C. The reaction was stopped by adding lithium dodecyl sulfate sample loading buffer (Invitrogen) and incubating at 95°C for 5 min. Proteins were electrophoretically separated through 12% sodium dodecyl sulfate-polyacrylamide gels (Invitrogen), and transferred to polyvinylidene difluoride membranes (Millipore). Non-specific membrane binding was blocked by incubation in 5% milk blocking solution (Bio-Rad) for 1 h. Membranes were then incubated for 1 h at room temperature with horseradish peroxidase-conjugated Bar224 anti-PrP monoclonal antibody (SPI bio) diluted 1:20,000 in Superblock (Pierce), washed 6 × 10 min in PBS with 0.2% Tween 20, and incubated for 5 min with enhanced chemiluminescent substrate (Millipore). Membranes were digitally photographed using the FujiDoc gel documentation system equipped with a cooled charge-coupled diode camera (Fuji). Densitometric analyses were performed using Quantity One software (Bio-Rad).
Prion inoculations and clinical scoring
Mice were anesthetized by Isofluorane inhalation. Thirty microliters of each inoculum was injected intracerebrally 3 mm deep through the coronal suture 3-5 mm lateral of the sagittal suture. Mice were monitored daily for clinical symptoms of prion disease, including tail rigidity, impaired extensor reflex, akinesia, tremors, ataxia, weight loss and paralysis. Mice with any four of these symptoms were scored terminally sick and euthanized.
Histochemistry and immunohistochemistry (IHC)
Tissues were fixed in 10% paraformaldehyde, embedded in paraffin and 5-10 μm sections mounted on glass slides. For PrP staining tissue sections were deparaffinized, treated with concentrated formic acid for 30 min, then autoclaved at 121°C in target retrieval solution (Dako) for 2 h, washed 2 × 2 min in 1× PBS, treated with 0.3% H 2 0 2 in methanol for 10 min and blocked for 15 min with 1% BSA in PBS. Sections were then incubated with horseradish peroxidase-conjugated anti-PrP Bar 224 monoclonal antibody diluted 1:100 in antibody diluent (Dako) for 1 h, rinsed 2 × 2 min in PBS, exposed to a Diaminobenzidine solution (Dako) for 2 min, rinsed 2 × 2 min in PBS and counterstained with hematoxylin. Slides were dehydrated in xylene and coverslips mounted with Cytoseal (Richard Allan Scientific). For Thioflavin T staining, sections were treated with 1% Thioflavin T in distilled water for 10 min at room temperature, followed by 1% acetic acid in water for 10 min and then rinsed with distilled water for 5 min. Hematoxylin and Eosin (H&E) and glial fibrillary acidic protein (GFAP) staining was performed on a NexES automated IHC stainer (Ventana Medical systems, Inc. Tucson, AZ). Sections were stained with H&E for 4 min at room temperature. Sections were stained with rabbit polyclonal antisera against GFAP (diluted 1:8) for 10 min at 37°C followed by Biotinylated goat anti-rabbit Ig (mouse/rat adsorbed) for 8 min, then counterstained with hematoxylin for 4 min. Sections were visualized and digitally photographed using an Olympus BX60 microscope equipped with a cooled charge-coupled diode camera.
Lesion profiling
Brain lesion profiling was performed as previously described (Fraser and Dickinson, 1968) with slight modifications. Ten neuroanatomic regions were identified in medial sagittal brain sections from at least six mice of each group: 1-dorsal medulla, 2-cerebellum, 3-superior colliculus, 4-red nucleus, 5-hypothalamus, 6-hippocampus, 7-thalamus, 8-cerebral cortex, 9-primary somatosensory cortex and 10-caudate-putamen. Four investigators blinded to group identification scored each region for vacuolation, astrogliosis and PrP RES deposition using the following severity scale: normal (0-1), mild (2), moderate (3) and severe (4). The average of the sum of the three scores constitutes the severity score for each region.
Conformational stability assay
Conformational stability assays were modified from a previous protocol (Xie et al., 2006) . 15 μl aliquots of brain homogenates were incubated for 1 h at room temperature with increasing concentrations of guanidine hydrochloride (GdnHCl, Sigma) ranging from 0 to 3.75 M in 0.375 M increments. Samples were precipitated in ice-cold methanol at −20°C overnight, centrifuged at 13,000 ×g for 30 min at 4°C. Pellets were washed in PMCA buffer and centrifuged 3×, resuspended in 18 μl of PMCA buffer, PK-digested and western blotted. Conformational stability was quantified by densitometric analyses of western blots, plotting the mean percentage of PrP RES remaining ±SD as a function of GdnHCl concentration, and using fourth order polynomial equations and nonlinear regression (GraphPad Prism) to fit denaturation curves for each prion strain.
Statistical analyses
One-way ANOVA with Tukey post-test analysis was performed using GraphPad Prism.
